OptiMAx: testing SQ-LNS to boost vaccination in rural Chad and Niger
Official title: OptiMAx: Incentivizing EPI Vaccination Via Distribution of SQ-LNS Nutritional Supplementation to Children From Age 6-11 Months Until 18 Months of Age in Rural Chad and Niger, With a Cost Effectiveness Analysis Protocol for a Research Study Nested in the OptiMA Research Study in Ngouri Health District, Lake Region, Chad and Mirriah Health District, Zinder Region, Niger
Run by Alliance for International Medical Action · NCT07592260 · Data updated 2026-11-12
This study tests whether giving small-batch SQ-LNS to young children helps increase routine immunizations in rural Chad and Niger.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 6 Months to 59 Months |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Alliance for International Medical Action Academic / other |
| Locations | 2 sites (Ngouri, Lac Region and 1 other locations) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | May 18, 2026 |
| Trial ID | NCT07592260 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are non-malnourished children aged 6–12 months living in the study areas of Ngouri, Chad, and Mirriah in Niger who can participate through age 18 months.
✕Probably not a fit
Children who are already malnourished or outside the age range may receive limited or no targeted benefit from this specific intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The OptiMAx program evaluates whether combining monthly SQ-LNS supplementation with immunization services improves vaccination coverage, particularly Pentavalent 3 and Measles 1, in children aged 12–23 months. It also looks at whether receiving SQ-LNS before malnutrition develops influences outcomes under the OptiMA protocol. The project includes household surveys, a mixed-methods process evaluation, and a gender sub-study conducted in rural sites in Chad and Niger, led by ALIMA with collaboration from academic and public health partners. Participants include infants 6–12 months who will receive SQ-LNS until 18 months, and caregivers and community members involved in implementation and evaluation. The study is conducted at Ngouri and Mirriah hospitals and involves data on malnutrition and vaccination uptake to inform potential policy and program design.
Why it matters
Potential benefit: If successful, the program could improve vaccination coverage and child health by linking nutrition supplementation with immunization services.
How similar studies have gone: Previous programs have shown that nutrition interventions can influence vaccination uptake in some settings, but results vary by context and implementation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All non-malnourished children between 6 and 12 months of age will be eligible for SQ-LNS supplementation until they reach 18 months of age. For the annual household surveys, * Children aged 6 to 59 months will be surveyed on MUAC status and other malnutrition-related issues, while the immunization analysis will focus on children aged 12 to 23 months; * With the informed oral consent of the parents or legal guardian ; * Reside in the neighborhoods included in the study. For the mixed-methods process evaluation and gender sub-study (to be carried out in the months following implementation). Inclusion criteria * OptiMAx intervention personnel (e.g. healthcare staff) * A group of mothers of children benefiting from the intervention * Male partners/spouses of parents * Community members from the sites targeted by the intervention will be recruited for the focus groups. * Non-adherents or parents who choose not to continue nutritional supplementation and/or vaccination despite their availability under the program will be recruited for interviews. * Husbands/male partners of non-members will also be surveyed. Exclusion Criteria: * Age-eligible children with MUAC \<125 or edema will first be treated for acute malnutrition with OptiMA and then resume supplementation with SQ-LNS. There is no exclusion criteria for the annual household surveys Exclusion criteria for the mixed-methods process evaluation \- Parents or guardians under 15 years of age.
Where it's running
-
Ngouri hospital
Ngouri, Lac Region, Chad Recruiting -
Mirriah hospital
Mirriah, Zinder Region, Niger Recruiting
Study contacts
- Principal investigator: Kevin Phelan, MSc — ALIMA - The Alliance for International Medical Action
- Study coordinator: Kevin Phelan, MSc
- Email: kevin.phelan@alima.ngo
- Phone: +33 664235628
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RSV vaccine safety and immune response in lung transplant patients vs. healthy adults
This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.
-
Sleep and Teens’ Immune Response to a Meningococcal Vaccine
This study checks if 11- to 12-year-olds’ sleep habits affect how well their vaccine for meningococcal disease works.
-
Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery
This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.
-
Using fingerprint-linked digital records and reminders to help children finish their malaria and routine vaccines
This project will test whether a biometric-linked digital vaccination system plus voice-message reminders can help children in Ghana complete their malaria and routine vaccines.
-
Which vaccine messages grab attention in rural New England
This online test uses short social-media vaccine messages delivered by either experts or influencers to see which ones better catch attention and influence attitudes among adults living in rural New England.
-
Neutralizing power of blood and nasal antibodies
This project will test how strong blood and nasal antibodies remain over time in adults getting COVID-19 or monkeypox vaccines or antibody treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.